The
protease inhibitors are predicted to inhibit the
metabolism of
mirtazapine by CYP3A4. Other CYP3A4 inhibitors (such as ketoconazole) have been shown to have this effect.
The manufacturers advise caution on concurrent use. Monitor for adverse effects (e.g. oedema, sedation).